---
document_datetime: 2023-11-24 12:16:07
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vimizim-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: vimizim-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.3817575
conversion_datetime: 2025-12-28 12:15:42.06429
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Vimizim

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0043              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 18/08/2023                          | 11/09/2023                                  |                                  |           |
| IB/0042/G            | This was an application for a group of variations.                                             | 01/08/2023                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place A.7 - Administrative change - Deletion of   |            |     |                |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------|
| IB/0041 | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 22/05/2023 | n/a |                |
| II/0040 | Please refer to the Recommendations section C.I.11.b - Introduction of, or change(s) to, the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 16/03/2023 | n/a | Not applicable |

<div style=\"page-break-after: always\"></div>

|           | obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                         |            |     |                |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------|
| II/0039   | Please refer to the Recommendations section B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                                                     | 12/01/2023 | n/a | Not applicable |
| II/0037/G | This was an application for a group of variations. Please refer to the Recommendations section B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test | 23/06/2022 | n/a | Not applicable |
| IA/0038   | B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits                                                                                                                                                                                                                                                                                              | 23/05/2022 | n/a |                |
| IA/0036/G | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved                                                                                                                                                                                                                                                                                                                               | 15/11/2021 | n/a |                |

<div style=\"page-break-after: always\"></div>

|                     | stability protocol B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10218 /202102 | Periodic Safety Update EU Single assessment - elosulfase alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 30/09/2021 | n/a | PRAC Recommendation - maintenance |
| II/0034             | Submission of an updated RMP version 5.2 in order to update the safety specifications (epidemiology of indication and target populations, exposures in clinical trials and post marketing), the pharmacovigilance plan (routine and additional pharmacovigilance activities). Addition of an infusion reaction targeted questionnaire as routine pharmacovigilance activity. Deletion of a training material in section V.1 and addition of a process indicator to evaluate the distribution of the educational materials. The RMP has also been updated in line with EU RMP template (revision 2.0.1). C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 09/04/2021 | n/a |                                   |
| IB/0033             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 09/09/2020 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | of the AS                                                                                                                                                                                                                              |            |            |                                  |                                                                                                                                                                                                                                                                       |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10218 /202002 | Periodic Safety Update EU Single assessment - elosulfase alfa                                                                                                                                                                          | 03/09/2020 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| IG/1141             | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 12/12/2019 | n/a        |                                  |                                                                                                                                                                                                                                                                       |
| IB/0030             | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                            | 27/09/2019 | n/a        |                                  |                                                                                                                                                                                                                                                                       |
| PSUSA/10218 /201902 | Periodic Safety Update EU Single assessment - elosulfase alfa                                                                                                                                                                          | 05/09/2019 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| IG/1083             | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 08/04/2019 | n/a        |                                  |                                                                                                                                                                                                                                                                       |
| IB/0027             | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                           | 26/02/2019 | n/a        |                                  |                                                                                                                                                                                                                                                                       |
| R/0024              | Renewal of the marketing authorisation.                                                                                                                                                                                                | 18/10/2018 | 20/12/2018 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Vimizim in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |

<div style=\"page-break-after: always\"></div>

| T/0026              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 31/07/2018   | 28/09/2018   | SmPC, Labelling and PL   |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------------------|
| PSUSA/10218 /201802 | Periodic Safety Update EU Single assessment - elosulfase alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 06/09/2018   | n/a          |                          | PRAC Recommendation - maintenance |
| IA/0025             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 11/07/2018   | n/a          |                          |                                   |
| II/0022/G           | This was an application for a group of variations. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 25/05/2018   | n/a          |                          |                                   |
| II/0021/G           | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 16/11/2017   | 27/09/2018   | Annex II                 |                                   |

<div style=\"page-break-after: always\"></div>

|                     | material [-] used in the manufacture of a biological/immunological product B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                       |            |            |                    |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|-----------------------------------|
| PSUSA/10218 /201702 | Periodic Safety Update EU Single assessment - elosulfase alfa                                                                                                                                                                                                                                                                                                               | 01/09/2017 | n/a        |                    | PRAC Recommendation - maintenance |
| IB/0020             | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                              | 30/08/2017 | 27/09/2018 | SmPC and Labelling |                                   |
| II/0017/G           | This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.II.f.1.e - Stability of FP - Change to an approved stability protocol | 15/06/2017 | n/a        |                    |                                   |
| IB/0019             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                            | 09/06/2017 | n/a        |                    |                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10218 /201608   | Periodic Safety Update EU Single assessment - elosulfase alfa                                                                                                                                                                                                                                                                | 09/03/2017   | n/a        |                        | PRAC Recommendation - maintenance   |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------|
| II/0015               | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol                                                                   | 28/10/2016   | n/a        |                        |                                     |
| PSUSA/10218 /201602   | Periodic Safety Update EU Single assessment - elosulfase alfa                                                                                                                                                                                                                                                                | 02/09/2016   | n/a        |                        | PRAC Recommendation - maintenance   |
| PSUSA/10218 /201508   | Periodic Safety Update EU Single assessment - elosulfase alfa                                                                                                                                                                                                                                                                | 17/03/2016   | n/a        |                        | PRAC Recommendation - maintenance   |
| IG/0658               | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                   | 02/02/2016   | 11/01/2017 | SmPC, Labelling and PL |                                     |
| IA/0012/G             | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process | 09/12/2015   | n/a        |                        |                                     |
| IG/0629               | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                           | 05/11/2015   | n/a        |                        |                                     |

<div style=\"page-break-after: always\"></div>

| IB/0009             | B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                      | 18/09/2015   | n/a        |             |                                                                                                                                                                                                                                                                                                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10218 /201502 | Periodic Safety Update EU Single assessment - elosulfase alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 10/09/2015   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                 |
| IB/0008             | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                     | 15/06/2015   | n/a        |             |                                                                                                                                                                                                                                                                                                                   |
| II/0006             | Update of section 4.2 of the SmPC in order to include information relating to possibility of home infusions under the supervision of a healthcare professional for patients who are tolerating their infusions well, in alignment with the submission of the MOR-100 study report. In addition, the Marketing authorisation holder (MAH) took the opportunity to make editorial changes in section 5.2 of the SmPC to improve clarity. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 26/03/2015   | 08/07/2015 | SmPC        | Information regarding the home infusion for Vimizim has been added after analysis of long term efficacy and safety data from study MOR-100. Home administration under the supervision of an appropriately trained healthcare professional may be considered for patients who are tolerating their infusions well. |
| PSUSA/10218 /201408 | Periodic Safety Update EU Single assessment - elosulfase alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 12/03/2015   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                 |
| II/0004             | Update of sections 5.1 and 4.8 of the Summary of Product Characteristics following 52 weeks results of                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 23/10/2014   | 08/07/2015 | SmPC and PL | After review of the submitted paediatric data, the following information was reflected in the product information:                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|         | clinical study MOR-007 conducted in paediatric patients with MPS IVA (under the age of 5 years). The date of latest revision is deleted in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                 | - Section 5.1: In an open-label trial, 15 paediatric patients with MPS IVA under the age of 5 years (9 months to <5 years) received 2 mg/kg of Vimizim once a week for 52 weeks. Safety and pharmacodynamic results in these patients are consistent with results observed in patients 5 to 57 years old (see sections 4.8). - Section 4.8: In patients < 5 years of age, the overall safety profile of Vimizim at 2 mg/kg/week was consistent with the safety profile of Vimizim observed in older children.   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0471 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                     | 04/08/2014 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IG/0458 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                          | 09/07/2014 | 08/07/2015 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |